ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
PAVmed Inc

PAVmed Inc (PAVM)

1.0284
-0.0016
( -0.16% )
Updated: 10:26:18

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.0284
Bid
1.01
Ask
1.05
Volume
17,020
1.01 Day's Range 1.085
0.5999 52 Week Range 4.875
Market Cap
Previous Close
1.03
Open
1.03
Last Trade
35
@
1.01
Last Trade Time
10:28:08
Financial Volume
$ 17,799
VWAP
1.0458
Average Volume (3m)
64,031
Shares Outstanding
11,068,566
Dividend Yield
-
PE Ratio
-0.18
Earnings Per Share (EPS)
-5.99
Revenue
2.45M
Net Profit
-66.27M

About PAVmed Inc

PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
PAVmed Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker PAVM. The last closing price for PAVmed was $1.03. Over the last year, PAVmed shares have traded in a share price range of $ 0.5999 to $ 4.875.

PAVmed currently has 11,068,566 shares outstanding. The market capitalization of PAVmed is $11.40 million. PAVmed has a price to earnings ratio (PE ratio) of -0.18.

PAVM Latest News

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 PR Newswire NEW YORK, Oct. 31, 2024 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 31, 2024...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 PR Newswire NEW YORK, Oct. 30, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, Oct...

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test PR Newswire NEW YORK, Oct. 15, 2024 Patent covers proprietary method using methylation of...

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care PR Newswire NEW YORK, Oct. 10, 2024 Grant will fund research to optimize Veris Cancer Care Platform for...

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit PR Newswire NEW YORK, Oct. 9, 2024 NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0217-2.066469860011.05011.1611126191.07269494CS
4-0.0216-2.057142857141.051.211523551.07315257CS
120.128414.26666666670.91.890.8640311.26806983CS
26-0.7716-42.86666666671.81.960.5999639931.11738332CS
52-2.1366-67.50710900473.1654.8750.59991006662.61723748CS
156-63.1716-98.398130841164.264.4250.599968498318.95622002CS
260-13.5216-92.931958762914.55145.50.5999115214447.13790098CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 2.15
(119.39%)
91.33M
SKKSKK Holdings Limited
$ 9.95
(118.20%)
4.11M
CRNCCerence Inc
$ 4.87
(72.70%)
17.99M
SURGSurgePays Inc
$ 2.4249
(66.09%)
4.16M
SPAISafe Pro Group Inc
$ 4.52
(41.25%)
36.61M
PYXSPyxis Oncology Inc
$ 2.095
(-45.16%)
7.42M
KURAKura Oncology Inc
$ 10.035
(-36.93%)
6.46M
SHOTWSafety Shot Inc
$ 0.1001
(-33.27%)
2.5k
BLRXBioLineRx Ltd
$ 0.3651
(-33.03%)
4.79M
AGFYAgrify Corporation
$ 26.9076
(-30.58%)
290.85k
CDTConduit Pharmaceuticals Inc
$ 0.12299
(33.25%)
441.18M
AKTSAkoustis Technologies Inc
$ 0.1018
(16.88%)
169.89M
NVDANVIDIA Corporation
$ 142.65
(-2.22%)
153.07M
WORXSCWorx Corporation
$ 2.14
(118.37%)
91.41M
ELABElevai Labs Inc
$ 0.02035
(-4.91%)
90.08M

PAVM Discussion

View Posts
Monksdream Monksdream 5 months ago
PAVM under $2
👍️0
Monksdream Monksdream 10 months ago
PAVM new 52 week low
👍️0
Monksdream Monksdream 11 months ago
PAVM new 52 week low
👍️0
Mattrixinvest Mattrixinvest 1 year ago
Boom
👍️0
Monksdream Monksdream 1 year ago
PAVM new 52 week low
👍️0
Porterhouse10 Porterhouse10 3 years ago
Boom! Haaa
👍️0
Thunderstruck Thunderstruck 3 years ago
PAVM....Why the drop?? wasn't there just good news out in regards to this company and Lucid??
👍️0
Prfmf1 Prfmf1 3 years ago
Looks like they are trying to keep the stock around or under $7.50 to burn the August 20 options holders.
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
not bullish...but bouncing. No microcaps are bullish right now...play with caution!!!
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 years ago
$PAVM Chart looking bullish here..
https://twitter.com/QuabbinR/status/1419357207557193733?s=20
👍️0
SurgeGuy2.0 SurgeGuy2.0 3 years ago
Was the CEO really arrested last week for fraud? Would it be the first time? Need to do a little more looking at it....right?
👍️0
SurgeGuy2.0 SurgeGuy2.0 3 years ago
Looking good like a stinky pile of crap. PAVM is going nowhere! lolzzzzzzzz
👍️0
bUrRpPPP! bUrRpPPP! 3 years ago
Looking good!
👍️0
Prfmf1 Prfmf1 3 years ago
What are your expectations going forward?
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
PAVM there's a monster breaking out of its chains!!
👍️0
Prfmf1 Prfmf1 3 years ago
Short time PAVM holder and looking for big things to happen with this stock. My average buying price is in the low 4's.
👍️0
Flycanuck Flycanuck 3 years ago
Thanks for the tip. Will have a look .
👍️0
Flycanuck Flycanuck 3 years ago
Got Z warrants and shares too. Have not sold yet. Holding through this run up.
👍️0
rumrunner528 rumrunner528 3 years ago
Thank you, ConstitutionNow.

rum
👍️0
ConstitutionNow ConstitutionNow 3 years ago
Visit stocktwits.com at all? Lots of long term holders on there that have a good pulse on what's happening. I know Lucid spinoff is in the works, 3 clinics in phoenix about to open for eso testing. Eso 'in stock' at like 180 clinics around US. Do some quick numbers on a each test and you can see revs could scale quickly. Throw in nexflo, carpx etc and pavmed could be a great long term investment.
👍️0
rumrunner528 rumrunner528 3 years ago
Good for you, ConstitutionNow. I have z's and shares and have been lightening my position as it's run up. I wish I knew what's going on other than the recent PRs.

rum
👍️0
ConstitutionNow ConstitutionNow 4 years ago
Need a message at the top other than Clay...bad luck anytime he posts. Still sittin on a pile of z warrants...very bright future here! Eso, carpx etc...
👍️0
ClayTrader ClayTrader 4 years ago
* * $PAVM Video Chart 04-06-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Bertsllc Bertsllc 4 years ago
Cantor Fitzgerald analysis upgraded PAVM to overweight with the new target of $8.00.

https://www.benzinga.com/news/21/03/20397441/cantor-fitzgerald-initiates-coverage-on-pavmed-with-overweight-rating-announces-price-target-of-8

👍️0
ConstitutionNow ConstitutionNow 4 years ago
Little late in response here, but good analysis of the latest money raise. Solid move by management to get debt off books, lower dilution and cash leftover to fund commercialization. I think the market is starting to realize it now and we should move north on much more solid ground...where they can raise more cash at prices which don't hurt so much.
👍️0
Flycanuck Flycanuck 4 years ago
from the March 2020 S-3A (link below - page 5), I counted about 14 million shares could have been issued by the convertibles. So actually longer term they have about 4 million shares LESS outstanding plus all the cash you mentioned above. Win / Win.
https://www.sec.gov/Archives/edgar/data/1624326/000149315220005215/forms-3a.htm
👍️0
Flycanuck Flycanuck 4 years ago
"PAVmed intends to use the net proceeds from the offering to repay all of the company’s outstanding debt, including all outstanding convertible notes, with the balance to be used for working capital and general corporate purposes."

People don't realize, this doesn't increase dilution. It's a near wash in shares added, becasue the outstanding convertible shares are taken off the books by paying off the convertible holders. It increases float, but not outstanding.

Then the proceeds pay off all other debt, and the company still has around 30M from the offering to use for operations. It's a huge win for the company and shareholders.
👍️0
ClayTrader ClayTrader 4 years ago
* * $PAVM Video Chart 02-22-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
tone3 tone3 4 years ago
Must read article on Seeking Alpha. Target prices from a low of 5.50 up to 12 bucks
👍️0
ConstitutionNow ConstitutionNow 4 years ago
No odea what you are talking about...posted on twitter???????????
👍️0
SurgeGuy2.0 SurgeGuy2.0 4 years ago
When will the new Offering/Dilution for 2021 be announced?

Saw it posted on twitter
👍️0
rumrunner528 rumrunner528 4 years ago
Thank you.
👍️0
ConstitutionNow ConstitutionNow 4 years ago
I've dug into those a bit, from what I can tell they are exercisable at a $1.60 a common share. Expire 2024. Slightly more risky than common but not much, if only one of their products take off, imo the warrants are much better investment dollar for dollar.
👍️0
rumrunner528 rumrunner528 4 years ago
👍️0
rumrunner528 rumrunner528 4 years ago
Does anyone know the terms of the PAVMZ warrants? The 10K is very confusing (or perhaps I'm just not that bright).
👍️0
jaj-dan jaj-dan 4 years ago
Gaining lots of credibility here.
👍️0
jaj-dan jaj-dan 4 years ago
PAVmed to join key indexes this month, shares +5% https://seekingalpha.com/news/3583795-pavmed-to-join-key-indexes-this-month-sharesplus-5
👍️0
jaj-dan jaj-dan 4 years ago
News from yesterday. Probably why the price is moving up.

Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor https://seekingalpha.com
👍️0
jaj-dan jaj-dan 4 years ago
I was just repeating the talking points from the conference call.
👍️0
Bickema Bickema 4 years ago
"PAVmed had cash and cash equivalents of $8.7 million as of March 31, 2020, compared with $6.2 million as of December 31, 2019. Subsequently, in late April 2020, the Company received approximately $3.6 million in proceeds from a private placement with an institutional investor for the sale of a Senior Secured Convertible Note."

Looks like they $12 million in cash no?
👍️0
Cubzgrl Cubzgrl 4 years ago
Moving north!!!! Lets get back to the $6.00s lol
👍️0
jaj-dan jaj-dan 4 years ago
https://ir.pavmed.com/news-events/press-releases/detail/121/pavmed-collaborates-with-canon-on-disappear-pediatric
👍️0
jaj-dan jaj-dan 4 years ago
PAVMed Is About To Enter The Commercialization Phase https://seekingalpha.com/article/4350867-pavmed-is-to-enter-commercialization-phase
👍️0
tjguy tjguy 4 years ago
Is the European approval of CarpX coming up soon?
👍️0
jaj-dan jaj-dan 5 years ago
I don’t really care if it dips here. There’s plenty of firms targeting this at $9-$10. It’s one of my best positions at the moment. I’m holding.
👍️0
jaj-dan jaj-dan 5 years ago
They didn’t really have much to say on the call. They were impacted by the virus with elective surgeries being postponed. They also commented that esoguard could be spun off into another company to raise money
👍️0
jaj-dan jaj-dan 5 years ago
There was only 1 analyst on the call. That’s not good. Management sounded very competent answering questions
👍️0
elcheepo elcheepo 5 years ago
thats a lot of cash they burned... they need to slow down
👍️0
jaj-dan jaj-dan 5 years ago
They said that their CarpX device will make 80-85% return
👍️0
jaj-dan jaj-dan 5 years ago
Re: PAVM
Some people may have bought hoping for a partnership deal announced. These things take time. You won't get a great deal if you are in a hurry.
👍️0